Mednet Logo
SpecialtiesRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

Do you offer SBRT Liver for patients with low platelets?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Mount Sinai Medical Center

The highest predictor for the development of HCC is cirrhosis, and with cirrhosis invariably comes portal HTN and low platelets. Almost all of our primary HCC patients have some degree of thrombocytopenia, many below 100,000. As such, we have treated them all without difficulty or complication. We w...

Does pre-chemotherapy extent of nodal involvement impact your decision to offer adjuvant radiation in cN1, ypN0 triple-negative breast cancer?

3
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Beth Israel Deaconess Medical Center

There are few data on this subject. The group at the Netherlands Cancer Institute in Amsterdam created what they called the "MARI" approach for such patients (Koolen et al., PMID 28524246). In brief, they performed an axillary ultrasound and marked the largest suspicious node with a radioactive seed...

How do you sequence chemotherapy with radiotherapy for advanced endometrial cancer?

6
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

Unfortunately, we don’t even know for sure if we need RT for stage III disease.GOG 258 showed early concurrent chemo RT is no better than chemotherapy alone (delaying chemo increased distant mets, which probably negated locoregional control benefit of RT). For this reason, chemotherapy has become st...

How do you manage PSA progression while a patient is on Xofigo or Pluvicto?

5
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Corewell Health

The tl;drPSA is very much an imperfect tool for these patients. The data show that PSA may initially increase over multiple cycles before decreasing, though this is a minority of patients. Most patients whose PSA increases early have resistant disease, and you should investigate further with imaging...

Would you treat a male breast cancer patient with post-mastectomy radiotherapy for a single positive sentinel lymph node and a low Oncotype?

2
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Allegheny Health Network, Pittsburgh

In the setting of a mastectomy with a positive SLN and no ALND, I tend to extrapolate from AMAROS. While Z0011 had no mastectomy and AMAROS limited mastectomy patients, I am comfortable extrapolating axillary management to mastectomy setting.In this case, I would offer PMRT to chest wall and regiona...

What target expansions do you use when treating with 60 Gy in 15 fractions for the lung?

6
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Texas MD Anderson Cancer Center

Is CTV needed with hypofractionated radiotherapy, such as 60 Gy in 15 fractions for stage III NSCLC, in the modern era of IGRT? Reducing the irradiated volume is crucial for improving the therapeutic ratio for locally advanced NSCLC (LA-NSCLC) patients. Technological advancements in radiotherapy tar...

Would you offer adjuvant chemotherapy or radiation to a resected MSS T3N0 high-rectal lesion with low anterior resection without pre-op therapy?

5
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · Mayo Clinic School of Medicine

For patients with T3N0 upper rectal cancer with no significant risk factors (R0, CRM clear, no EMVI) who undergo high quality TME surgery as suggested by an intact TME pathologic specimen, the 5-year risk of pelvic recurrence without the delivery of adjuvant radiotherapy is < 5%. I do not recommend ...

Should high risk prostate cancer patients be placed on more potent ADT (abiraterone or enzalutamide) in the upfront setting with definitive RT instead of the standard LHRH agonist?

3
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · AdventHealth Cancer Institute

With STAMPEDE suggesting improvement with the addition of abiraterone in very high risk N0 patients, this is certainly becoming a consideration. Duke is completing a trial of concurrent abiraterone/STADT/definitive radiation for intermediate and lower high risk prostate cancer. Results forthcoming. ...

How do you approach liver SBRT in patients with hepatocellular carcinoma who aren't candidates for surgery or other interventional procedures when the overall liver volume is small making it difficult to achieve liver constraints?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Cincinnati College of Medicine

These are tough situations. I have used proton and photons for HCC. In the situation you described, I would generally favor IMPT due to improved low dose distribution and keeping the parenchyma not treated to a minimum while still giving an ablative dose more comfortably. Although the mean liver dos...

What neoadjuvant approach is best for an adenocarcinoma of the GE junction (arising in Barrett's) with a large hiatal hernia?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Moffitt Cancer Center

I haven't found any publication or clinical trial regarding this very incidental finding. However, I had the opportunity of discussing in tumor board a similar case. I suggested to consider surgical management of the hiatal hernia first, and shortly after recovering, proceed with chemotherapy and ra...